What You Should Know:
– Omniscient (o8t®), a Sydney, Australia-based global leader in applying AI to unlock the secrets of the human brain, announced today the successful conclusion of its Series C funding round. This round brings the company’s total capital raised to US$60M , marking a significant milestone in its growth trajectory.
– The funding round highlights the confidence of prominent Australian investors, including Will Vicars and Gina Rinehart, in Omniscient’s vision and capabilities.
– Omniscient’s technology empowers clinicians and patients across various brain health specialties. From neurosurgery and neurology to mental health and beyond, Omniscient is poised to revolutionize how we understand and treat brain conditions.
Pioneering Connectomics with AI
Omniscient stands at the forefront of connectomics, a field that utilizes AI to map and analyze the intricate web of connections within the human brain. This groundbreaking technology offers a deeper understanding of brain function and dysfunction, paving the way for advancements in brain health diagnosis and treatment.
Brain Mapping: The Future of Brain Health
Omniscient’s platform Quicktome utilizes AI to analyze a standard MRI scan and create a detailed map of an individual’s brain networks. This technology has recently expanded to include the first FDA-cleared neurological planning and visualization tool using resting-state fMRI. This opens doors for new applications in areas like stroke, disorders of consciousness, and oncology.
Market Expansion Plans
Omniscient plans to leverage the new funds for two key initiatives:
- US Market Expansion: The company aims to solidify its presence in the US market, where over 100 hospitals and clinics already utilize their flagship AI platform, Quicktome®.
- Product Development: Omniscient will invest in expanding Quicktome’s capabilities to address a broader range of brain health conditions.
“At Omniscient, we create meaningful AI-driven technologies that are transforming how we understand and care for the brain. Our innovations empower doctors, therapeutics developers, and brain tech pioneers to make groundbreaking advances in brain science and treatment,” said Dr. Stephane Doyen, Chief Data Scientist and co-founder of Omniscient.
